SMC approves lenvatinib plus everolimus combination for second-line treatment of advanced kidney cancer

We are delighted to announce that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines in Scotland, has published advice recommending the routine use of lenvatinib plus everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior VEGF-targeted therapy by NHS Scotland. The lenvatinib plus everolimus combination was accepted following consideration […]

read more

Avelumab as a first- or second-line treatment for metastatic kidney cancer

A recent study looked at the efficacy and safety of first- or second-line avelumab (an anti–PD-L1 immunotherapy) in patients with metastatic clear cell renal cell carcinoma (RCC). A total of 62 patients were treated with avelumab in the first-line (intravenous infusion every 2 weeks) and 20 patients were treated with avelumab in the second-line. Most […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

Kidney cancer surgery in older patients

The RESURGE project retrospectively analysed data from three published studies including 1871 patients with renal cell carcinoma (RCC) from 24 hospitals. This study looked at outcomes of surgery (radical or partial nephrectomy) in older patients aged over 75 years. The study concluded that surgery for kidney cancer is feasible and safe in well-selected older patients. […]

read more

Lenvatinib plus pembrolizumab combination shows promise in metastatic kidney cancer

Interim results from an ongoing clinical trial of lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma (RCC) who have already received an immune checkpoint inhibitor. The trial included up to 360 patients with various cancers, of which 33 patients had metastatic clear cell RCC. The patients took a […]

read more

Sunitinib and pazopanib for non-clear cell and sarcomatoid kidney cancer

Non-clear cell renal cell carcinoma (RCC) and sarcomatoid renal cell carcinoma are often treated similarly to clear cell RCC with the tyrosine kinase inhibitors, sunitinib and pazopanib. A recent study investigated the effectiveness of these two drugs for the first-line treatment of metastatic non-clear cell and sarcomatoid RCC. Of the 53 patients included in the […]

read more

Negative effect on survival of kidney cancer patients of immediate sunitinib dose interruption

A recent study looked at the impact of stopping sunitinib during the first two cycles of treatment for metastatic renal cell carcinoma (RCC). Ninety-seven patients were analysed retrospectively and divided into two groups; those who had a dose interruption during the first two cycles of sunitinib treatment and those who did not. Thirty-eight patients (39.2%) […]

read more

Potential new treatments for kidney cancer discussed at 2019 Kidney Cancer Research Summit

In this interview from the 2019 Kidney Cancer Research Summit and published in the journal CURE, Dr Sumanta Pal, a medical oncologist at City of Hope, California, USA discusses the expanding field of kidney cancer treatment and what this means for patients with renal cell carcinoma (RCC). During the interview, Dr Pal discusses the use […]

read more

Treatment with stereotactic body radiotherapy plus TKIs or immunotherapy is safe and may improve survival of metastatic kidney cancer patients

Two small studies looked at the addition of a type of radiotherapy treatment, called stereotactic body radiotherapy (SBRT), to treatment with a tyrosine kinase inhibitor (TKI), such as sunitinib or pazopanib, or a checkpoint inhibitor, such as nivolumab for patients with metastatic renal cell carcinoma (RCC). In the first study, 56 patients with metastatic RCC […]

read more

New subtypes of kidney cancer identified

Using advanced proteogenomic technologies to look at genetic makeup and proteins, researchers from the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) in America have identified four subtypes of clear cell renal cell carcinoma (RCC). The researchers found that almost all of the clear cell RCC tumour samples in the study lacked chromosome 3p. […]

read more
Showing 1 to 10 of 635 results
  TOP